Potential role of circulating microRNAs (486-5p, 497, 509-5p and 605) in metabolic syndrome Egyptian male patients

Mohamed Bakr Zaki,1 Ahmed Ibrahim Abulsoud,1,2 Ahmed Mohamed Elsisi,2,3 Ahmed Soliman Doghish,2,4 Ossama Abd Elmotaal Mansour,2 Ashraf Ismail Amin,5 Mahmoud Ahmed Elrebehy,4 Mohamed Yousef Mohamed,6 Mohamed Ahmed Goda61Biochemistry Department, Faculty of Pharmacy, Heliopolis University, El-Nahda, Cairo Governorate 11777, Egypt; 2Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, 13465, Egypt; 3Biochemistry Department, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt; 4Biochemistry Department, Faculty of Pharmacy, Badr University in Cairo, Badr City, Cairo, Egypt; 5Department of Chemical and Clinical Pathology, National Institute of Diabetes and Endocrinology, Kasr El Ainy, Cairo, Egypt; 6Clinical Pharmacy Department, Faculty of Pharmacy (boys), Al-Azhar University, Nasr City, Cairo 13465, EgyptObjective: This study aims to evaluate the expression pattern of circulating microRNAs (miR)-486-5p, miR-497, miR-509-5p, and miR-605 in the serum of metabolic syndrome (MetS) Egyptian male patients.Methods: In this study, the circulating miR-486-5p, miR-497, miR509-5p, and miR-605 were amplified and quantitatively detected by quantitative real-time polymerase chain reaction in sera of 55 MetS male patients in comparison to 20 male controls. The level of fasting plasma glucose and triacylglycerol (TAG) were measured using calorimetric assay. Blood pressure was measured using mercuric sphygmomanometer. Anthropometric measurements were done to each individual. Furthermore, MetS patients were defined according to the criteria proposed by the American Heart Association and divided into three groups according to MetS index.Results: The study was performed on three groups and a control group defined as follows: group 1: 15 MetS patients who fulfilled all diagnostic criteria of MetS; group 2: 20 MetS patients with normal blood pressure; group 3: 20 MetS patients with normal TAG levels.The levels of miRs are expressed as [median (IQR)]. miR-486-5-p and miR-497 expression were elevated in group 1 [31.9(49), p˂0.0001; 73.1(42.5), p˂0.0001], group 2 [36.4(15.7), p˂0.0001; 68.3(54.8), p˂0.0001], and group (3) [10.8(18.9), p=0.0014; 27.5(39.7), p=0.0012]. MiR-509-5p was elevated in groups 1 and 2 [501(468), p=0.0001], [309(436), p=0.0006], respectively, while normally expressed in group 3 [0.93(0.077), p=0.0001]. miR-605 was elevated in groups 1 and 3 [25.4(20.0), p=0.0018], [54.8(65.8), p˂0.0001], while normally expressed in group 2 [0.84(0.67), p˂0.0001].Conclusion: miRs (486-5p, 497, 509-5p, and 605) serum levels were higher in MetS patients than in healthy control subjects; therefore, these serum miRs can serve as early biomarkers and can be used to follow-up the prognosis of MetS.Keywords: metabolic syndrome (MetS), miR-486-5p, miR-497, miR509-5p, miR-605, metabolic syndrome index (MSI) Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Bakr Zaki M [verfasserIn] Abulsoud AI [verfasserIn] Elsisi AM [verfasserIn] Doghish AS [verfasserIn] Mansour OAE [verfasserIn] Amin AI [verfasserIn] Elrebehy MA [verfasserIn] Mohamed MY [verfasserIn] Goda MA [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2019

Schlagwörter:	Metabolic Syndrome (MetS) miR-486-5p miR-497 miR509-5p miR-605 Metabolic Syndrome Index (MSI).

Übergeordnetes Werk:	In: Diabetes, Metabolic Syndrome and Obesity - Dove Medical Press, 2009, (2019), Seite 601-611
Übergeordnetes Werk:	year:2019 ; pages:601-611

Links:	Link aufrufen Link aufrufen Journal toc

Katalog-ID:	DOAJ072749954

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ072749954
003	DE-627
005	20230310201251.0
007	cr uuu---uuuuu
008	230228s2019 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)DOAJ072749954
035			\|a (DE-599)DOAJf4523351f0cc4e7296ee3f3244025424
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC581-951
100	0		\|a Bakr Zaki M \|e verfasserin \|4 aut
245	1	0	\|a Potential role of circulating microRNAs (486-5p, 497, 509-5p and 605) in metabolic syndrome Egyptian male patients
264		1	\|c 2019
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Mohamed Bakr Zaki,1 Ahmed Ibrahim Abulsoud,1,2 Ahmed Mohamed Elsisi,2,3 Ahmed Soliman Doghish,2,4 Ossama Abd Elmotaal Mansour,2 Ashraf Ismail Amin,5 Mahmoud Ahmed Elrebehy,4 Mohamed Yousef Mohamed,6 Mohamed Ahmed Goda61Biochemistry Department, Faculty of Pharmacy, Heliopolis University, El-Nahda, Cairo Governorate 11777, Egypt; 2Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, 13465, Egypt; 3Biochemistry Department, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt; 4Biochemistry Department, Faculty of Pharmacy, Badr University in Cairo, Badr City, Cairo, Egypt; 5Department of Chemical and Clinical Pathology, National Institute of Diabetes and Endocrinology, Kasr El Ainy, Cairo, Egypt; 6Clinical Pharmacy Department, Faculty of Pharmacy (boys), Al-Azhar University, Nasr City, Cairo 13465, EgyptObjective: This study aims to evaluate the expression pattern of circulating microRNAs (miR)-486-5p, miR-497, miR-509-5p, and miR-605 in the serum of metabolic syndrome (MetS) Egyptian male patients.Methods: In this study, the circulating miR-486-5p, miR-497, miR509-5p, and miR-605 were amplified and quantitatively detected by quantitative real-time polymerase chain reaction in sera of 55 MetS male patients in comparison to 20 male controls. The level of fasting plasma glucose and triacylglycerol (TAG) were measured using calorimetric assay. Blood pressure was measured using mercuric sphygmomanometer. Anthropometric measurements were done to each individual. Furthermore, MetS patients were defined according to the criteria proposed by the American Heart Association and divided into three groups according to MetS index.Results: The study was performed on three groups and a control group defined as follows: group 1: 15 MetS patients who fulfilled all diagnostic criteria of MetS; group 2: 20 MetS patients with normal blood pressure; group 3: 20 MetS patients with normal TAG levels.The levels of miRs are expressed as [median (IQR)]. miR-486-5-p and miR-497 expression were elevated in group 1 [31.9(49), p˂0.0001; 73.1(42.5), p˂0.0001], group 2 [36.4(15.7), p˂0.0001; 68.3(54.8), p˂0.0001], and group (3) [10.8(18.9), p=0.0014; 27.5(39.7), p=0.0012]. MiR-509-5p was elevated in groups 1 and 2 [501(468), p=0.0001], [309(436), p=0.0006], respectively, while normally expressed in group 3 [0.93(0.077), p=0.0001]. miR-605 was elevated in groups 1 and 3 [25.4(20.0), p=0.0018], [54.8(65.8), p˂0.0001], while normally expressed in group 2 [0.84(0.67), p˂0.0001].Conclusion: miRs (486-5p, 497, 509-5p, and 605) serum levels were higher in MetS patients than in healthy control subjects; therefore, these serum miRs can serve as early biomarkers and can be used to follow-up the prognosis of MetS.Keywords: metabolic syndrome (MetS), miR-486-5p, miR-497, miR509-5p, miR-605, metabolic syndrome index (MSI)
650		4	\|a Metabolic Syndrome (MetS)
650		4	\|a miR-486-5p
650		4	\|a miR-497
650		4	\|a miR509-5p
650		4	\|a miR-605
650		4	\|a Metabolic Syndrome Index (MSI).
653		0	\|a Specialties of internal medicine
700	0		\|a Abulsoud AI \|e verfasserin \|4 aut
700	0		\|a Elsisi AM \|e verfasserin \|4 aut
700	0		\|a Doghish AS \|e verfasserin \|4 aut
700	0		\|a Mansour OAE \|e verfasserin \|4 aut
700	0		\|a Amin AI \|e verfasserin \|4 aut
700	0		\|a Elrebehy MA \|e verfasserin \|4 aut
700	0		\|a Mohamed MY \|e verfasserin \|4 aut
700	0		\|a Goda MA \|e verfasserin \|4 aut
773	0	8	\|i In \|t Diabetes, Metabolic Syndrome and Obesity \|d Dove Medical Press, 2009 \|g (2019), Seite 601-611 \|w (DE-627)60030597X \|w (DE-600)2494854-8 \|x 11787007 \|7 nnns
773	1	8	\|g year:2019 \|g pages:601-611
856	4	0	\|u https://doaj.org/article/f4523351f0cc4e7296ee3f3244025424 \|z kostenfrei
856	4	0	\|u https://www.dovepress.com/potential-role-of-circulating-micrornas-486-5p-497-509-5p-and-605-in-m-peer-reviewed-article-DMSO \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1178-7007 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|j 2019 \|h 601-611

Indexfelder

author_variant	b z m bzm a a aa e a ea d a da m o mo a a aa e m em m m mm g m gm
matchkey_str	article:11787007:2019----::oetarlocruaigirra46p959pn65neaoisn
hierarchy_sort_str	2019
callnumber-subject-code	RC
publishDate	2019
allfields	(DE-627)DOAJ072749954 (DE-599)DOAJf4523351f0cc4e7296ee3f3244025424 DE-627 ger DE-627 rakwb eng RC581-951 Bakr Zaki M verfasserin aut Potential role of circulating microRNAs (486-5p, 497, 509-5p and 605) in metabolic syndrome Egyptian male patients 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Mohamed Bakr Zaki,1 Ahmed Ibrahim Abulsoud,1,2 Ahmed Mohamed Elsisi,2,3 Ahmed Soliman Doghish,2,4 Ossama Abd Elmotaal Mansour,2 Ashraf Ismail Amin,5 Mahmoud Ahmed Elrebehy,4 Mohamed Yousef Mohamed,6 Mohamed Ahmed Goda61Biochemistry Department, Faculty of Pharmacy, Heliopolis University, El-Nahda, Cairo Governorate 11777, Egypt; 2Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, 13465, Egypt; 3Biochemistry Department, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt; 4Biochemistry Department, Faculty of Pharmacy, Badr University in Cairo, Badr City, Cairo, Egypt; 5Department of Chemical and Clinical Pathology, National Institute of Diabetes and Endocrinology, Kasr El Ainy, Cairo, Egypt; 6Clinical Pharmacy Department, Faculty of Pharmacy (boys), Al-Azhar University, Nasr City, Cairo 13465, EgyptObjective: This study aims to evaluate the expression pattern of circulating microRNAs (miR)-486-5p, miR-497, miR-509-5p, and miR-605 in the serum of metabolic syndrome (MetS) Egyptian male patients.Methods: In this study, the circulating miR-486-5p, miR-497, miR509-5p, and miR-605 were amplified and quantitatively detected by quantitative real-time polymerase chain reaction in sera of 55 MetS male patients in comparison to 20 male controls. The level of fasting plasma glucose and triacylglycerol (TAG) were measured using calorimetric assay. Blood pressure was measured using mercuric sphygmomanometer. Anthropometric measurements were done to each individual. Furthermore, MetS patients were defined according to the criteria proposed by the American Heart Association and divided into three groups according to MetS index.Results: The study was performed on three groups and a control group defined as follows: group 1: 15 MetS patients who fulfilled all diagnostic criteria of MetS; group 2: 20 MetS patients with normal blood pressure; group 3: 20 MetS patients with normal TAG levels.The levels of miRs are expressed as [median (IQR)]. miR-486-5-p and miR-497 expression were elevated in group 1 [31.9(49), p˂0.0001; 73.1(42.5), p˂0.0001], group 2 [36.4(15.7), p˂0.0001; 68.3(54.8), p˂0.0001], and group (3) [10.8(18.9), p=0.0014; 27.5(39.7), p=0.0012]. MiR-509-5p was elevated in groups 1 and 2 [501(468), p=0.0001], [309(436), p=0.0006], respectively, while normally expressed in group 3 [0.93(0.077), p=0.0001]. miR-605 was elevated in groups 1 and 3 [25.4(20.0), p=0.0018], [54.8(65.8), p˂0.0001], while normally expressed in group 2 [0.84(0.67), p˂0.0001].Conclusion: miRs (486-5p, 497, 509-5p, and 605) serum levels were higher in MetS patients than in healthy control subjects; therefore, these serum miRs can serve as early biomarkers and can be used to follow-up the prognosis of MetS.Keywords: metabolic syndrome (MetS), miR-486-5p, miR-497, miR509-5p, miR-605, metabolic syndrome index (MSI) Metabolic Syndrome (MetS) miR-486-5p miR-497 miR509-5p miR-605 Metabolic Syndrome Index (MSI). Specialties of internal medicine Abulsoud AI verfasserin aut Elsisi AM verfasserin aut Doghish AS verfasserin aut Mansour OAE verfasserin aut Amin AI verfasserin aut Elrebehy MA verfasserin aut Mohamed MY verfasserin aut Goda MA verfasserin aut In Diabetes, Metabolic Syndrome and Obesity Dove Medical Press, 2009 (2019), Seite 601-611 (DE-627)60030597X (DE-600)2494854-8 11787007 nnns year:2019 pages:601-611 https://doaj.org/article/f4523351f0cc4e7296ee3f3244025424 kostenfrei https://www.dovepress.com/potential-role-of-circulating-micrornas-486-5p-497-509-5p-and-605-in-m-peer-reviewed-article-DMSO kostenfrei https://doaj.org/toc/1178-7007 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2019 601-611
spelling	(DE-627)DOAJ072749954 (DE-599)DOAJf4523351f0cc4e7296ee3f3244025424 DE-627 ger DE-627 rakwb eng RC581-951 Bakr Zaki M verfasserin aut Potential role of circulating microRNAs (486-5p, 497, 509-5p and 605) in metabolic syndrome Egyptian male patients 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Mohamed Bakr Zaki,1 Ahmed Ibrahim Abulsoud,1,2 Ahmed Mohamed Elsisi,2,3 Ahmed Soliman Doghish,2,4 Ossama Abd Elmotaal Mansour,2 Ashraf Ismail Amin,5 Mahmoud Ahmed Elrebehy,4 Mohamed Yousef Mohamed,6 Mohamed Ahmed Goda61Biochemistry Department, Faculty of Pharmacy, Heliopolis University, El-Nahda, Cairo Governorate 11777, Egypt; 2Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, 13465, Egypt; 3Biochemistry Department, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt; 4Biochemistry Department, Faculty of Pharmacy, Badr University in Cairo, Badr City, Cairo, Egypt; 5Department of Chemical and Clinical Pathology, National Institute of Diabetes and Endocrinology, Kasr El Ainy, Cairo, Egypt; 6Clinical Pharmacy Department, Faculty of Pharmacy (boys), Al-Azhar University, Nasr City, Cairo 13465, EgyptObjective: This study aims to evaluate the expression pattern of circulating microRNAs (miR)-486-5p, miR-497, miR-509-5p, and miR-605 in the serum of metabolic syndrome (MetS) Egyptian male patients.Methods: In this study, the circulating miR-486-5p, miR-497, miR509-5p, and miR-605 were amplified and quantitatively detected by quantitative real-time polymerase chain reaction in sera of 55 MetS male patients in comparison to 20 male controls. The level of fasting plasma glucose and triacylglycerol (TAG) were measured using calorimetric assay. Blood pressure was measured using mercuric sphygmomanometer. Anthropometric measurements were done to each individual. Furthermore, MetS patients were defined according to the criteria proposed by the American Heart Association and divided into three groups according to MetS index.Results: The study was performed on three groups and a control group defined as follows: group 1: 15 MetS patients who fulfilled all diagnostic criteria of MetS; group 2: 20 MetS patients with normal blood pressure; group 3: 20 MetS patients with normal TAG levels.The levels of miRs are expressed as [median (IQR)]. miR-486-5-p and miR-497 expression were elevated in group 1 [31.9(49), p˂0.0001; 73.1(42.5), p˂0.0001], group 2 [36.4(15.7), p˂0.0001; 68.3(54.8), p˂0.0001], and group (3) [10.8(18.9), p=0.0014; 27.5(39.7), p=0.0012]. MiR-509-5p was elevated in groups 1 and 2 [501(468), p=0.0001], [309(436), p=0.0006], respectively, while normally expressed in group 3 [0.93(0.077), p=0.0001]. miR-605 was elevated in groups 1 and 3 [25.4(20.0), p=0.0018], [54.8(65.8), p˂0.0001], while normally expressed in group 2 [0.84(0.67), p˂0.0001].Conclusion: miRs (486-5p, 497, 509-5p, and 605) serum levels were higher in MetS patients than in healthy control subjects; therefore, these serum miRs can serve as early biomarkers and can be used to follow-up the prognosis of MetS.Keywords: metabolic syndrome (MetS), miR-486-5p, miR-497, miR509-5p, miR-605, metabolic syndrome index (MSI) Metabolic Syndrome (MetS) miR-486-5p miR-497 miR509-5p miR-605 Metabolic Syndrome Index (MSI). Specialties of internal medicine Abulsoud AI verfasserin aut Elsisi AM verfasserin aut Doghish AS verfasserin aut Mansour OAE verfasserin aut Amin AI verfasserin aut Elrebehy MA verfasserin aut Mohamed MY verfasserin aut Goda MA verfasserin aut In Diabetes, Metabolic Syndrome and Obesity Dove Medical Press, 2009 (2019), Seite 601-611 (DE-627)60030597X (DE-600)2494854-8 11787007 nnns year:2019 pages:601-611 https://doaj.org/article/f4523351f0cc4e7296ee3f3244025424 kostenfrei https://www.dovepress.com/potential-role-of-circulating-micrornas-486-5p-497-509-5p-and-605-in-m-peer-reviewed-article-DMSO kostenfrei https://doaj.org/toc/1178-7007 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2019 601-611
allfields_unstemmed	(DE-627)DOAJ072749954 (DE-599)DOAJf4523351f0cc4e7296ee3f3244025424 DE-627 ger DE-627 rakwb eng RC581-951 Bakr Zaki M verfasserin aut Potential role of circulating microRNAs (486-5p, 497, 509-5p and 605) in metabolic syndrome Egyptian male patients 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Mohamed Bakr Zaki,1 Ahmed Ibrahim Abulsoud,1,2 Ahmed Mohamed Elsisi,2,3 Ahmed Soliman Doghish,2,4 Ossama Abd Elmotaal Mansour,2 Ashraf Ismail Amin,5 Mahmoud Ahmed Elrebehy,4 Mohamed Yousef Mohamed,6 Mohamed Ahmed Goda61Biochemistry Department, Faculty of Pharmacy, Heliopolis University, El-Nahda, Cairo Governorate 11777, Egypt; 2Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, 13465, Egypt; 3Biochemistry Department, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt; 4Biochemistry Department, Faculty of Pharmacy, Badr University in Cairo, Badr City, Cairo, Egypt; 5Department of Chemical and Clinical Pathology, National Institute of Diabetes and Endocrinology, Kasr El Ainy, Cairo, Egypt; 6Clinical Pharmacy Department, Faculty of Pharmacy (boys), Al-Azhar University, Nasr City, Cairo 13465, EgyptObjective: This study aims to evaluate the expression pattern of circulating microRNAs (miR)-486-5p, miR-497, miR-509-5p, and miR-605 in the serum of metabolic syndrome (MetS) Egyptian male patients.Methods: In this study, the circulating miR-486-5p, miR-497, miR509-5p, and miR-605 were amplified and quantitatively detected by quantitative real-time polymerase chain reaction in sera of 55 MetS male patients in comparison to 20 male controls. The level of fasting plasma glucose and triacylglycerol (TAG) were measured using calorimetric assay. Blood pressure was measured using mercuric sphygmomanometer. Anthropometric measurements were done to each individual. Furthermore, MetS patients were defined according to the criteria proposed by the American Heart Association and divided into three groups according to MetS index.Results: The study was performed on three groups and a control group defined as follows: group 1: 15 MetS patients who fulfilled all diagnostic criteria of MetS; group 2: 20 MetS patients with normal blood pressure; group 3: 20 MetS patients with normal TAG levels.The levels of miRs are expressed as [median (IQR)]. miR-486-5-p and miR-497 expression were elevated in group 1 [31.9(49), p˂0.0001; 73.1(42.5), p˂0.0001], group 2 [36.4(15.7), p˂0.0001; 68.3(54.8), p˂0.0001], and group (3) [10.8(18.9), p=0.0014; 27.5(39.7), p=0.0012]. MiR-509-5p was elevated in groups 1 and 2 [501(468), p=0.0001], [309(436), p=0.0006], respectively, while normally expressed in group 3 [0.93(0.077), p=0.0001]. miR-605 was elevated in groups 1 and 3 [25.4(20.0), p=0.0018], [54.8(65.8), p˂0.0001], while normally expressed in group 2 [0.84(0.67), p˂0.0001].Conclusion: miRs (486-5p, 497, 509-5p, and 605) serum levels were higher in MetS patients than in healthy control subjects; therefore, these serum miRs can serve as early biomarkers and can be used to follow-up the prognosis of MetS.Keywords: metabolic syndrome (MetS), miR-486-5p, miR-497, miR509-5p, miR-605, metabolic syndrome index (MSI) Metabolic Syndrome (MetS) miR-486-5p miR-497 miR509-5p miR-605 Metabolic Syndrome Index (MSI). Specialties of internal medicine Abulsoud AI verfasserin aut Elsisi AM verfasserin aut Doghish AS verfasserin aut Mansour OAE verfasserin aut Amin AI verfasserin aut Elrebehy MA verfasserin aut Mohamed MY verfasserin aut Goda MA verfasserin aut In Diabetes, Metabolic Syndrome and Obesity Dove Medical Press, 2009 (2019), Seite 601-611 (DE-627)60030597X (DE-600)2494854-8 11787007 nnns year:2019 pages:601-611 https://doaj.org/article/f4523351f0cc4e7296ee3f3244025424 kostenfrei https://www.dovepress.com/potential-role-of-circulating-micrornas-486-5p-497-509-5p-and-605-in-m-peer-reviewed-article-DMSO kostenfrei https://doaj.org/toc/1178-7007 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2019 601-611
allfieldsGer	(DE-627)DOAJ072749954 (DE-599)DOAJf4523351f0cc4e7296ee3f3244025424 DE-627 ger DE-627 rakwb eng RC581-951 Bakr Zaki M verfasserin aut Potential role of circulating microRNAs (486-5p, 497, 509-5p and 605) in metabolic syndrome Egyptian male patients 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Mohamed Bakr Zaki,1 Ahmed Ibrahim Abulsoud,1,2 Ahmed Mohamed Elsisi,2,3 Ahmed Soliman Doghish,2,4 Ossama Abd Elmotaal Mansour,2 Ashraf Ismail Amin,5 Mahmoud Ahmed Elrebehy,4 Mohamed Yousef Mohamed,6 Mohamed Ahmed Goda61Biochemistry Department, Faculty of Pharmacy, Heliopolis University, El-Nahda, Cairo Governorate 11777, Egypt; 2Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, 13465, Egypt; 3Biochemistry Department, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt; 4Biochemistry Department, Faculty of Pharmacy, Badr University in Cairo, Badr City, Cairo, Egypt; 5Department of Chemical and Clinical Pathology, National Institute of Diabetes and Endocrinology, Kasr El Ainy, Cairo, Egypt; 6Clinical Pharmacy Department, Faculty of Pharmacy (boys), Al-Azhar University, Nasr City, Cairo 13465, EgyptObjective: This study aims to evaluate the expression pattern of circulating microRNAs (miR)-486-5p, miR-497, miR-509-5p, and miR-605 in the serum of metabolic syndrome (MetS) Egyptian male patients.Methods: In this study, the circulating miR-486-5p, miR-497, miR509-5p, and miR-605 were amplified and quantitatively detected by quantitative real-time polymerase chain reaction in sera of 55 MetS male patients in comparison to 20 male controls. The level of fasting plasma glucose and triacylglycerol (TAG) were measured using calorimetric assay. Blood pressure was measured using mercuric sphygmomanometer. Anthropometric measurements were done to each individual. Furthermore, MetS patients were defined according to the criteria proposed by the American Heart Association and divided into three groups according to MetS index.Results: The study was performed on three groups and a control group defined as follows: group 1: 15 MetS patients who fulfilled all diagnostic criteria of MetS; group 2: 20 MetS patients with normal blood pressure; group 3: 20 MetS patients with normal TAG levels.The levels of miRs are expressed as [median (IQR)]. miR-486-5-p and miR-497 expression were elevated in group 1 [31.9(49), p˂0.0001; 73.1(42.5), p˂0.0001], group 2 [36.4(15.7), p˂0.0001; 68.3(54.8), p˂0.0001], and group (3) [10.8(18.9), p=0.0014; 27.5(39.7), p=0.0012]. MiR-509-5p was elevated in groups 1 and 2 [501(468), p=0.0001], [309(436), p=0.0006], respectively, while normally expressed in group 3 [0.93(0.077), p=0.0001]. miR-605 was elevated in groups 1 and 3 [25.4(20.0), p=0.0018], [54.8(65.8), p˂0.0001], while normally expressed in group 2 [0.84(0.67), p˂0.0001].Conclusion: miRs (486-5p, 497, 509-5p, and 605) serum levels were higher in MetS patients than in healthy control subjects; therefore, these serum miRs can serve as early biomarkers and can be used to follow-up the prognosis of MetS.Keywords: metabolic syndrome (MetS), miR-486-5p, miR-497, miR509-5p, miR-605, metabolic syndrome index (MSI) Metabolic Syndrome (MetS) miR-486-5p miR-497 miR509-5p miR-605 Metabolic Syndrome Index (MSI). Specialties of internal medicine Abulsoud AI verfasserin aut Elsisi AM verfasserin aut Doghish AS verfasserin aut Mansour OAE verfasserin aut Amin AI verfasserin aut Elrebehy MA verfasserin aut Mohamed MY verfasserin aut Goda MA verfasserin aut In Diabetes, Metabolic Syndrome and Obesity Dove Medical Press, 2009 (2019), Seite 601-611 (DE-627)60030597X (DE-600)2494854-8 11787007 nnns year:2019 pages:601-611 https://doaj.org/article/f4523351f0cc4e7296ee3f3244025424 kostenfrei https://www.dovepress.com/potential-role-of-circulating-micrornas-486-5p-497-509-5p-and-605-in-m-peer-reviewed-article-DMSO kostenfrei https://doaj.org/toc/1178-7007 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2019 601-611
allfieldsSound	(DE-627)DOAJ072749954 (DE-599)DOAJf4523351f0cc4e7296ee3f3244025424 DE-627 ger DE-627 rakwb eng RC581-951 Bakr Zaki M verfasserin aut Potential role of circulating microRNAs (486-5p, 497, 509-5p and 605) in metabolic syndrome Egyptian male patients 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Mohamed Bakr Zaki,1 Ahmed Ibrahim Abulsoud,1,2 Ahmed Mohamed Elsisi,2,3 Ahmed Soliman Doghish,2,4 Ossama Abd Elmotaal Mansour,2 Ashraf Ismail Amin,5 Mahmoud Ahmed Elrebehy,4 Mohamed Yousef Mohamed,6 Mohamed Ahmed Goda61Biochemistry Department, Faculty of Pharmacy, Heliopolis University, El-Nahda, Cairo Governorate 11777, Egypt; 2Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, 13465, Egypt; 3Biochemistry Department, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt; 4Biochemistry Department, Faculty of Pharmacy, Badr University in Cairo, Badr City, Cairo, Egypt; 5Department of Chemical and Clinical Pathology, National Institute of Diabetes and Endocrinology, Kasr El Ainy, Cairo, Egypt; 6Clinical Pharmacy Department, Faculty of Pharmacy (boys), Al-Azhar University, Nasr City, Cairo 13465, EgyptObjective: This study aims to evaluate the expression pattern of circulating microRNAs (miR)-486-5p, miR-497, miR-509-5p, and miR-605 in the serum of metabolic syndrome (MetS) Egyptian male patients.Methods: In this study, the circulating miR-486-5p, miR-497, miR509-5p, and miR-605 were amplified and quantitatively detected by quantitative real-time polymerase chain reaction in sera of 55 MetS male patients in comparison to 20 male controls. The level of fasting plasma glucose and triacylglycerol (TAG) were measured using calorimetric assay. Blood pressure was measured using mercuric sphygmomanometer. Anthropometric measurements were done to each individual. Furthermore, MetS patients were defined according to the criteria proposed by the American Heart Association and divided into three groups according to MetS index.Results: The study was performed on three groups and a control group defined as follows: group 1: 15 MetS patients who fulfilled all diagnostic criteria of MetS; group 2: 20 MetS patients with normal blood pressure; group 3: 20 MetS patients with normal TAG levels.The levels of miRs are expressed as [median (IQR)]. miR-486-5-p and miR-497 expression were elevated in group 1 [31.9(49), p˂0.0001; 73.1(42.5), p˂0.0001], group 2 [36.4(15.7), p˂0.0001; 68.3(54.8), p˂0.0001], and group (3) [10.8(18.9), p=0.0014; 27.5(39.7), p=0.0012]. MiR-509-5p was elevated in groups 1 and 2 [501(468), p=0.0001], [309(436), p=0.0006], respectively, while normally expressed in group 3 [0.93(0.077), p=0.0001]. miR-605 was elevated in groups 1 and 3 [25.4(20.0), p=0.0018], [54.8(65.8), p˂0.0001], while normally expressed in group 2 [0.84(0.67), p˂0.0001].Conclusion: miRs (486-5p, 497, 509-5p, and 605) serum levels were higher in MetS patients than in healthy control subjects; therefore, these serum miRs can serve as early biomarkers and can be used to follow-up the prognosis of MetS.Keywords: metabolic syndrome (MetS), miR-486-5p, miR-497, miR509-5p, miR-605, metabolic syndrome index (MSI) Metabolic Syndrome (MetS) miR-486-5p miR-497 miR509-5p miR-605 Metabolic Syndrome Index (MSI). Specialties of internal medicine Abulsoud AI verfasserin aut Elsisi AM verfasserin aut Doghish AS verfasserin aut Mansour OAE verfasserin aut Amin AI verfasserin aut Elrebehy MA verfasserin aut Mohamed MY verfasserin aut Goda MA verfasserin aut In Diabetes, Metabolic Syndrome and Obesity Dove Medical Press, 2009 (2019), Seite 601-611 (DE-627)60030597X (DE-600)2494854-8 11787007 nnns year:2019 pages:601-611 https://doaj.org/article/f4523351f0cc4e7296ee3f3244025424 kostenfrei https://www.dovepress.com/potential-role-of-circulating-micrornas-486-5p-497-509-5p-and-605-in-m-peer-reviewed-article-DMSO kostenfrei https://doaj.org/toc/1178-7007 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2019 601-611
language	English
source	In Diabetes, Metabolic Syndrome and Obesity (2019), Seite 601-611 year:2019 pages:601-611
sourceStr	In Diabetes, Metabolic Syndrome and Obesity (2019), Seite 601-611 year:2019 pages:601-611
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Metabolic Syndrome (MetS) miR-486-5p miR-497 miR509-5p miR-605 Metabolic Syndrome Index (MSI). Specialties of internal medicine
isfreeaccess_bool	true
container_title	Diabetes, Metabolic Syndrome and Obesity
authorswithroles_txt_mv	Bakr Zaki M @@aut@@ Abulsoud AI @@aut@@ Elsisi AM @@aut@@ Doghish AS @@aut@@ Mansour OAE @@aut@@ Amin AI @@aut@@ Elrebehy MA @@aut@@ Mohamed MY @@aut@@ Goda MA @@aut@@
publishDateDaySort_date	2019-01-01T00:00:00Z
hierarchy_top_id	60030597X
id	DOAJ072749954
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ072749954</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310201251.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2019 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ072749954</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf4523351f0cc4e7296ee3f3244025424</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-951</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Bakr Zaki M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Potential role of circulating microRNAs (486-5p, 497, 509-5p and 605) in metabolic syndrome Egyptian male patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Mohamed Bakr Zaki,1 Ahmed Ibrahim Abulsoud,1,2 Ahmed Mohamed Elsisi,2,3 Ahmed Soliman Doghish,2,4 Ossama Abd Elmotaal Mansour,2 Ashraf Ismail Amin,5 Mahmoud Ahmed Elrebehy,4 Mohamed Yousef Mohamed,6 Mohamed Ahmed Goda61Biochemistry Department, Faculty of Pharmacy, Heliopolis University, El-Nahda, Cairo Governorate 11777, Egypt; 2Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, 13465, Egypt; 3Biochemistry Department, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt; 4Biochemistry Department, Faculty of Pharmacy, Badr University in Cairo, Badr City, Cairo, Egypt; 5Department of Chemical and Clinical Pathology, National Institute of Diabetes and Endocrinology, Kasr El Ainy, Cairo, Egypt; 6Clinical Pharmacy Department, Faculty of Pharmacy (boys), Al-Azhar University, Nasr City, Cairo 13465, EgyptObjective: This study aims to evaluate the expression pattern of circulating microRNAs (miR)-486-5p, miR-497, miR-509-5p, and miR-605 in the serum of metabolic syndrome (MetS) Egyptian male patients.Methods: In this study, the circulating miR-486-5p, miR-497, miR509-5p, and miR-605 were amplified and quantitatively detected by quantitative real-time polymerase chain reaction in sera of 55 MetS male patients in comparison to 20 male controls. The level of fasting plasma glucose and triacylglycerol (TAG) were measured using calorimetric assay. Blood pressure was measured using mercuric sphygmomanometer. Anthropometric measurements were done to each individual. Furthermore, MetS patients were defined according to the criteria proposed by the American Heart Association and divided into three groups according to MetS index.Results: The study was performed on three groups and a control group defined as follows: group 1: 15 MetS patients who fulfilled all diagnostic criteria of MetS; group 2: 20 MetS patients with normal blood pressure; group 3: 20 MetS patients with normal TAG levels.The levels of miRs are expressed as [median (IQR)]. miR-486-5-p and miR-497 expression were elevated in group 1 [31.9(49), p˂0.0001; 73.1(42.5), p˂0.0001], group 2 [36.4(15.7), p˂0.0001; 68.3(54.8), p˂0.0001], and group (3) [10.8(18.9), p=0.0014; 27.5(39.7), p=0.0012]. MiR-509-5p was elevated in groups 1 and 2 [501(468), p=0.0001], [309(436), p=0.0006], respectively, while normally expressed in group 3 [0.93(0.077), p=0.0001]. miR-605 was elevated in groups 1 and 3 [25.4(20.0), p=0.0018], [54.8(65.8), p˂0.0001], while normally expressed in group 2 [0.84(0.67), p˂0.0001].Conclusion: miRs (486-5p, 497, 509-5p, and 605) serum levels were higher in MetS patients than in healthy control subjects; therefore, these serum miRs can serve as early biomarkers and can be used to follow-up the prognosis of MetS.Keywords: metabolic syndrome (MetS), miR-486-5p, miR-497, miR509-5p, miR-605, metabolic syndrome index (MSI)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Metabolic Syndrome (MetS)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">miR-486-5p</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">miR-497</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">miR509-5p</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">miR-605</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Metabolic Syndrome Index (MSI).</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Specialties of internal medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Abulsoud AI</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elsisi AM</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Doghish AS</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mansour OAE</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Amin AI</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elrebehy MA</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mohamed MY</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Goda MA</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Diabetes, Metabolic Syndrome and Obesity</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2019), Seite 601-611</subfield><subfield code="w">(DE-627)60030597X</subfield><subfield code="w">(DE-600)2494854-8</subfield><subfield code="x">11787007</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2019</subfield><subfield code="g">pages:601-611</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f4523351f0cc4e7296ee3f3244025424</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/potential-role-of-circulating-micrornas-486-5p-497-509-5p-and-605-in-m-peer-reviewed-article-DMSO</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-7007</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2019</subfield><subfield code="h">601-611</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Bakr Zaki M
spellingShingle	Bakr Zaki M misc RC581-951 misc Metabolic Syndrome (MetS) misc miR-486-5p misc miR-497 misc miR509-5p misc miR-605 misc Metabolic Syndrome Index (MSI). misc Specialties of internal medicine Potential role of circulating microRNAs (486-5p, 497, 509-5p and 605) in metabolic syndrome Egyptian male patients
authorStr	Bakr Zaki M
ppnlink_with_tag_str_mv	@@773@@(DE-627)60030597X
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC581-951
illustrated	Not Illustrated
issn	11787007
topic_title	RC581-951 Potential role of circulating microRNAs (486-5p, 497, 509-5p and 605) in metabolic syndrome Egyptian male patients Metabolic Syndrome (MetS) miR-486-5p miR-497 miR509-5p miR-605 Metabolic Syndrome Index (MSI)
topic	misc RC581-951 misc Metabolic Syndrome (MetS) misc miR-486-5p misc miR-497 misc miR509-5p misc miR-605 misc Metabolic Syndrome Index (MSI). misc Specialties of internal medicine
topic_unstemmed	misc RC581-951 misc Metabolic Syndrome (MetS) misc miR-486-5p misc miR-497 misc miR509-5p misc miR-605 misc Metabolic Syndrome Index (MSI). misc Specialties of internal medicine
topic_browse	misc RC581-951 misc Metabolic Syndrome (MetS) misc miR-486-5p misc miR-497 misc miR509-5p misc miR-605 misc Metabolic Syndrome Index (MSI). misc Specialties of internal medicine
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Diabetes, Metabolic Syndrome and Obesity
hierarchy_parent_id	60030597X
hierarchy_top_title	Diabetes, Metabolic Syndrome and Obesity
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)60030597X (DE-600)2494854-8
title	Potential role of circulating microRNAs (486-5p, 497, 509-5p and 605) in metabolic syndrome Egyptian male patients
ctrlnum	(DE-627)DOAJ072749954 (DE-599)DOAJf4523351f0cc4e7296ee3f3244025424
title_full	Potential role of circulating microRNAs (486-5p, 497, 509-5p and 605) in metabolic syndrome Egyptian male patients
author_sort	Bakr Zaki M
journal	Diabetes, Metabolic Syndrome and Obesity
journalStr	Diabetes, Metabolic Syndrome and Obesity
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2019
contenttype_str_mv	txt
container_start_page	601
author_browse	Bakr Zaki M Abulsoud AI Elsisi AM Doghish AS Mansour OAE Amin AI Elrebehy MA Mohamed MY Goda MA
class	RC581-951
format_se	Elektronische Aufsätze
author-letter	Bakr Zaki M
author2-role	verfasserin
title_sort	potential role of circulating micrornas (486-5p, 497, 509-5p and 605) in metabolic syndrome egyptian male patients
callnumber	RC581-951
title_auth	Potential role of circulating microRNAs (486-5p, 497, 509-5p and 605) in metabolic syndrome Egyptian male patients
abstract	Mohamed Bakr Zaki,1 Ahmed Ibrahim Abulsoud,1,2 Ahmed Mohamed Elsisi,2,3 Ahmed Soliman Doghish,2,4 Ossama Abd Elmotaal Mansour,2 Ashraf Ismail Amin,5 Mahmoud Ahmed Elrebehy,4 Mohamed Yousef Mohamed,6 Mohamed Ahmed Goda61Biochemistry Department, Faculty of Pharmacy, Heliopolis University, El-Nahda, Cairo Governorate 11777, Egypt; 2Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, 13465, Egypt; 3Biochemistry Department, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt; 4Biochemistry Department, Faculty of Pharmacy, Badr University in Cairo, Badr City, Cairo, Egypt; 5Department of Chemical and Clinical Pathology, National Institute of Diabetes and Endocrinology, Kasr El Ainy, Cairo, Egypt; 6Clinical Pharmacy Department, Faculty of Pharmacy (boys), Al-Azhar University, Nasr City, Cairo 13465, EgyptObjective: This study aims to evaluate the expression pattern of circulating microRNAs (miR)-486-5p, miR-497, miR-509-5p, and miR-605 in the serum of metabolic syndrome (MetS) Egyptian male patients.Methods: In this study, the circulating miR-486-5p, miR-497, miR509-5p, and miR-605 were amplified and quantitatively detected by quantitative real-time polymerase chain reaction in sera of 55 MetS male patients in comparison to 20 male controls. The level of fasting plasma glucose and triacylglycerol (TAG) were measured using calorimetric assay. Blood pressure was measured using mercuric sphygmomanometer. Anthropometric measurements were done to each individual. Furthermore, MetS patients were defined according to the criteria proposed by the American Heart Association and divided into three groups according to MetS index.Results: The study was performed on three groups and a control group defined as follows: group 1: 15 MetS patients who fulfilled all diagnostic criteria of MetS; group 2: 20 MetS patients with normal blood pressure; group 3: 20 MetS patients with normal TAG levels.The levels of miRs are expressed as [median (IQR)]. miR-486-5-p and miR-497 expression were elevated in group 1 [31.9(49), p˂0.0001; 73.1(42.5), p˂0.0001], group 2 [36.4(15.7), p˂0.0001; 68.3(54.8), p˂0.0001], and group (3) [10.8(18.9), p=0.0014; 27.5(39.7), p=0.0012]. MiR-509-5p was elevated in groups 1 and 2 [501(468), p=0.0001], [309(436), p=0.0006], respectively, while normally expressed in group 3 [0.93(0.077), p=0.0001]. miR-605 was elevated in groups 1 and 3 [25.4(20.0), p=0.0018], [54.8(65.8), p˂0.0001], while normally expressed in group 2 [0.84(0.67), p˂0.0001].Conclusion: miRs (486-5p, 497, 509-5p, and 605) serum levels were higher in MetS patients than in healthy control subjects; therefore, these serum miRs can serve as early biomarkers and can be used to follow-up the prognosis of MetS.Keywords: metabolic syndrome (MetS), miR-486-5p, miR-497, miR509-5p, miR-605, metabolic syndrome index (MSI)
abstractGer	Mohamed Bakr Zaki,1 Ahmed Ibrahim Abulsoud,1,2 Ahmed Mohamed Elsisi,2,3 Ahmed Soliman Doghish,2,4 Ossama Abd Elmotaal Mansour,2 Ashraf Ismail Amin,5 Mahmoud Ahmed Elrebehy,4 Mohamed Yousef Mohamed,6 Mohamed Ahmed Goda61Biochemistry Department, Faculty of Pharmacy, Heliopolis University, El-Nahda, Cairo Governorate 11777, Egypt; 2Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, 13465, Egypt; 3Biochemistry Department, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt; 4Biochemistry Department, Faculty of Pharmacy, Badr University in Cairo, Badr City, Cairo, Egypt; 5Department of Chemical and Clinical Pathology, National Institute of Diabetes and Endocrinology, Kasr El Ainy, Cairo, Egypt; 6Clinical Pharmacy Department, Faculty of Pharmacy (boys), Al-Azhar University, Nasr City, Cairo 13465, EgyptObjective: This study aims to evaluate the expression pattern of circulating microRNAs (miR)-486-5p, miR-497, miR-509-5p, and miR-605 in the serum of metabolic syndrome (MetS) Egyptian male patients.Methods: In this study, the circulating miR-486-5p, miR-497, miR509-5p, and miR-605 were amplified and quantitatively detected by quantitative real-time polymerase chain reaction in sera of 55 MetS male patients in comparison to 20 male controls. The level of fasting plasma glucose and triacylglycerol (TAG) were measured using calorimetric assay. Blood pressure was measured using mercuric sphygmomanometer. Anthropometric measurements were done to each individual. Furthermore, MetS patients were defined according to the criteria proposed by the American Heart Association and divided into three groups according to MetS index.Results: The study was performed on three groups and a control group defined as follows: group 1: 15 MetS patients who fulfilled all diagnostic criteria of MetS; group 2: 20 MetS patients with normal blood pressure; group 3: 20 MetS patients with normal TAG levels.The levels of miRs are expressed as [median (IQR)]. miR-486-5-p and miR-497 expression were elevated in group 1 [31.9(49), p˂0.0001; 73.1(42.5), p˂0.0001], group 2 [36.4(15.7), p˂0.0001; 68.3(54.8), p˂0.0001], and group (3) [10.8(18.9), p=0.0014; 27.5(39.7), p=0.0012]. MiR-509-5p was elevated in groups 1 and 2 [501(468), p=0.0001], [309(436), p=0.0006], respectively, while normally expressed in group 3 [0.93(0.077), p=0.0001]. miR-605 was elevated in groups 1 and 3 [25.4(20.0), p=0.0018], [54.8(65.8), p˂0.0001], while normally expressed in group 2 [0.84(0.67), p˂0.0001].Conclusion: miRs (486-5p, 497, 509-5p, and 605) serum levels were higher in MetS patients than in healthy control subjects; therefore, these serum miRs can serve as early biomarkers and can be used to follow-up the prognosis of MetS.Keywords: metabolic syndrome (MetS), miR-486-5p, miR-497, miR509-5p, miR-605, metabolic syndrome index (MSI)
abstract_unstemmed	Mohamed Bakr Zaki,1 Ahmed Ibrahim Abulsoud,1,2 Ahmed Mohamed Elsisi,2,3 Ahmed Soliman Doghish,2,4 Ossama Abd Elmotaal Mansour,2 Ashraf Ismail Amin,5 Mahmoud Ahmed Elrebehy,4 Mohamed Yousef Mohamed,6 Mohamed Ahmed Goda61Biochemistry Department, Faculty of Pharmacy, Heliopolis University, El-Nahda, Cairo Governorate 11777, Egypt; 2Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, 13465, Egypt; 3Biochemistry Department, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt; 4Biochemistry Department, Faculty of Pharmacy, Badr University in Cairo, Badr City, Cairo, Egypt; 5Department of Chemical and Clinical Pathology, National Institute of Diabetes and Endocrinology, Kasr El Ainy, Cairo, Egypt; 6Clinical Pharmacy Department, Faculty of Pharmacy (boys), Al-Azhar University, Nasr City, Cairo 13465, EgyptObjective: This study aims to evaluate the expression pattern of circulating microRNAs (miR)-486-5p, miR-497, miR-509-5p, and miR-605 in the serum of metabolic syndrome (MetS) Egyptian male patients.Methods: In this study, the circulating miR-486-5p, miR-497, miR509-5p, and miR-605 were amplified and quantitatively detected by quantitative real-time polymerase chain reaction in sera of 55 MetS male patients in comparison to 20 male controls. The level of fasting plasma glucose and triacylglycerol (TAG) were measured using calorimetric assay. Blood pressure was measured using mercuric sphygmomanometer. Anthropometric measurements were done to each individual. Furthermore, MetS patients were defined according to the criteria proposed by the American Heart Association and divided into three groups according to MetS index.Results: The study was performed on three groups and a control group defined as follows: group 1: 15 MetS patients who fulfilled all diagnostic criteria of MetS; group 2: 20 MetS patients with normal blood pressure; group 3: 20 MetS patients with normal TAG levels.The levels of miRs are expressed as [median (IQR)]. miR-486-5-p and miR-497 expression were elevated in group 1 [31.9(49), p˂0.0001; 73.1(42.5), p˂0.0001], group 2 [36.4(15.7), p˂0.0001; 68.3(54.8), p˂0.0001], and group (3) [10.8(18.9), p=0.0014; 27.5(39.7), p=0.0012]. MiR-509-5p was elevated in groups 1 and 2 [501(468), p=0.0001], [309(436), p=0.0006], respectively, while normally expressed in group 3 [0.93(0.077), p=0.0001]. miR-605 was elevated in groups 1 and 3 [25.4(20.0), p=0.0018], [54.8(65.8), p˂0.0001], while normally expressed in group 2 [0.84(0.67), p˂0.0001].Conclusion: miRs (486-5p, 497, 509-5p, and 605) serum levels were higher in MetS patients than in healthy control subjects; therefore, these serum miRs can serve as early biomarkers and can be used to follow-up the prognosis of MetS.Keywords: metabolic syndrome (MetS), miR-486-5p, miR-497, miR509-5p, miR-605, metabolic syndrome index (MSI)
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
title_short	Potential role of circulating microRNAs (486-5p, 497, 509-5p and 605) in metabolic syndrome Egyptian male patients
url	https://doaj.org/article/f4523351f0cc4e7296ee3f3244025424 https://www.dovepress.com/potential-role-of-circulating-micrornas-486-5p-497-509-5p-and-605-in-m-peer-reviewed-article-DMSO https://doaj.org/toc/1178-7007
remote_bool	true
author2	Abulsoud AI Elsisi AM Doghish AS Mansour OAE Amin AI Elrebehy MA Mohamed MY Goda MA
author2Str	Abulsoud AI Elsisi AM Doghish AS Mansour OAE Amin AI Elrebehy MA Mohamed MY Goda MA
ppnlink	60030597X
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
callnumber-a	RC581-951
up_date	2024-07-03T13:51:28.005Z
_version_	1803566121494773760
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ072749954</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310201251.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2019 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ072749954</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf4523351f0cc4e7296ee3f3244025424</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-951</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Bakr Zaki M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Potential role of circulating microRNAs (486-5p, 497, 509-5p and 605) in metabolic syndrome Egyptian male patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Mohamed Bakr Zaki,1 Ahmed Ibrahim Abulsoud,1,2 Ahmed Mohamed Elsisi,2,3 Ahmed Soliman Doghish,2,4 Ossama Abd Elmotaal Mansour,2 Ashraf Ismail Amin,5 Mahmoud Ahmed Elrebehy,4 Mohamed Yousef Mohamed,6 Mohamed Ahmed Goda61Biochemistry Department, Faculty of Pharmacy, Heliopolis University, El-Nahda, Cairo Governorate 11777, Egypt; 2Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, 13465, Egypt; 3Biochemistry Department, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt; 4Biochemistry Department, Faculty of Pharmacy, Badr University in Cairo, Badr City, Cairo, Egypt; 5Department of Chemical and Clinical Pathology, National Institute of Diabetes and Endocrinology, Kasr El Ainy, Cairo, Egypt; 6Clinical Pharmacy Department, Faculty of Pharmacy (boys), Al-Azhar University, Nasr City, Cairo 13465, EgyptObjective: This study aims to evaluate the expression pattern of circulating microRNAs (miR)-486-5p, miR-497, miR-509-5p, and miR-605 in the serum of metabolic syndrome (MetS) Egyptian male patients.Methods: In this study, the circulating miR-486-5p, miR-497, miR509-5p, and miR-605 were amplified and quantitatively detected by quantitative real-time polymerase chain reaction in sera of 55 MetS male patients in comparison to 20 male controls. The level of fasting plasma glucose and triacylglycerol (TAG) were measured using calorimetric assay. Blood pressure was measured using mercuric sphygmomanometer. Anthropometric measurements were done to each individual. Furthermore, MetS patients were defined according to the criteria proposed by the American Heart Association and divided into three groups according to MetS index.Results: The study was performed on three groups and a control group defined as follows: group 1: 15 MetS patients who fulfilled all diagnostic criteria of MetS; group 2: 20 MetS patients with normal blood pressure; group 3: 20 MetS patients with normal TAG levels.The levels of miRs are expressed as [median (IQR)]. miR-486-5-p and miR-497 expression were elevated in group 1 [31.9(49), p˂0.0001; 73.1(42.5), p˂0.0001], group 2 [36.4(15.7), p˂0.0001; 68.3(54.8), p˂0.0001], and group (3) [10.8(18.9), p=0.0014; 27.5(39.7), p=0.0012]. MiR-509-5p was elevated in groups 1 and 2 [501(468), p=0.0001], [309(436), p=0.0006], respectively, while normally expressed in group 3 [0.93(0.077), p=0.0001]. miR-605 was elevated in groups 1 and 3 [25.4(20.0), p=0.0018], [54.8(65.8), p˂0.0001], while normally expressed in group 2 [0.84(0.67), p˂0.0001].Conclusion: miRs (486-5p, 497, 509-5p, and 605) serum levels were higher in MetS patients than in healthy control subjects; therefore, these serum miRs can serve as early biomarkers and can be used to follow-up the prognosis of MetS.Keywords: metabolic syndrome (MetS), miR-486-5p, miR-497, miR509-5p, miR-605, metabolic syndrome index (MSI)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Metabolic Syndrome (MetS)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">miR-486-5p</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">miR-497</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">miR509-5p</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">miR-605</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Metabolic Syndrome Index (MSI).</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Specialties of internal medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Abulsoud AI</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elsisi AM</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Doghish AS</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mansour OAE</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Amin AI</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elrebehy MA</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mohamed MY</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Goda MA</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Diabetes, Metabolic Syndrome and Obesity</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2019), Seite 601-611</subfield><subfield code="w">(DE-627)60030597X</subfield><subfield code="w">(DE-600)2494854-8</subfield><subfield code="x">11787007</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2019</subfield><subfield code="g">pages:601-611</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f4523351f0cc4e7296ee3f3244025424</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/potential-role-of-circulating-micrornas-486-5p-497-509-5p-and-605-in-m-peer-reviewed-article-DMSO</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-7007</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2019</subfield><subfield code="h">601-611</subfield></datafield></record></collection>
score	7.4013853

Nicht das Richtige dabei?

Schreiben Sie uns!

Potential role of circulating microRNAs (486-5p, 497, 509-5p and 605) in metabolic syndrome Egyptian male patients

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?